The AVITA Therapeutics Inc (ASX: AVH) share price is pushing higher on Monday following the release of an announcement.
At the time of writing, the regenerative medicine company’s shares are up over 2.5% to $6.10.
Why is the AVITA share price pushing higher?
Investors have been buying the company’s shares this morning after it announced a preclinical research collaboration with Houston Methodist Research Institute.
According to the release, the collaboration will see the pairing of AVITA’s proprietary Spray-On Skin Cells with Houston Methodist Research Institute’s expertise in reversing cellular ageing.
The project is ultimately seeking to establish proof-of-concept for the development of a novel approach to reverse ageing and rejuvenate skin. It also includes the potential for broader applicability, such as scar revision and wound healing.
In addition to this, AVITA has entered into an option agreement to negotiate an exclusive, worldwide license to this patented technology for skin applications. It also has the first right of negotiation to technologies emerging from the collaboration for potential further development and commercialisation.
Management commentary.
AVITA Therapeutics’ Chief Executive Officer, Dr. Mike Perry, commented: “The Houston Methodist Research Institute is at the forefront of developing cutting-edge approaches for reversing cellular aging, and we look forward to working together on the exploration of combining their technology with AVITA Therapeutics’ proprietary Spray-on Skin Cells to rejuvenate aging skin.”
“This collaboration expands our pipeline to include exploration of modified-cells delivery and is another milestone in our commitment to harnessing the promise of regenerative medicine and unlocking the full potential of our technology platform to improve patients’ lives through skin restoration,” he added.
This sentiment was echoed by the Houston Methodist Research Institute.
The Institute’s Chair of the Department of Cardiovascular Sciences, John Cooke, M.D., Ph.D., commented: “AVITA Therapeutics’ innovative platform has advanced care for burn patients, and we are encouraged by the progress we have seen with our technology in improving cell function through our progeria research.”
“We look forward to collaborating with AVITA to combine our respective technology platforms to explore a potential new approach to reverse aging and improve functionality of skin. Our experience in RNAbased methods to regenerate blood vessels and reverse age-related endotheliopathy is directly relevant to skin repair and rejuvenation,” he concluded.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post AVITA Therapeutics (ASX:AVH) share price climbs higher on reverse ageing project appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3pdMdqC
Leave a Reply